TY - JOUR
T1 - Next-generation optimized biotherapeutics - A review and preclinical study
AU - Ueda, Tadashi
N1 - Publisher Copyright:
© 2014 Elsevier B.V.
PY - 2014/11
Y1 - 2014/11
N2 - Biotherapeutics have been clinically used since the 1990s. Recently, next-generation optimized biotherapeutics, which are expected to act on the same molecular target as their predecessors with further properties by antibody-drug conjugation, radiolabeling, PEGylation and glycoconjugation, are on the market. This article reviews recent next-generation optimized biotherapeutics. Moreover, since trials of protein engineering for biotherapeutics have been conducted, these preclinical approaches are also described. This article is part of a Special Issue entitled: Recent advances in molecular engineering of antibody.
AB - Biotherapeutics have been clinically used since the 1990s. Recently, next-generation optimized biotherapeutics, which are expected to act on the same molecular target as their predecessors with further properties by antibody-drug conjugation, radiolabeling, PEGylation and glycoconjugation, are on the market. This article reviews recent next-generation optimized biotherapeutics. Moreover, since trials of protein engineering for biotherapeutics have been conducted, these preclinical approaches are also described. This article is part of a Special Issue entitled: Recent advances in molecular engineering of antibody.
UR - http://www.scopus.com/inward/record.url?scp=84907904595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907904595&partnerID=8YFLogxK
U2 - 10.1016/j.bbapap.2014.06.008
DO - 10.1016/j.bbapap.2014.06.008
M3 - Review article
AN - SCOPUS:84907904595
VL - 1844
SP - 2053
EP - 2057
JO - Biochimica et Biophysica Acta - Proteins and Proteomics
JF - Biochimica et Biophysica Acta - Proteins and Proteomics
SN - 1570-9639
IS - 11
ER -